Mass Tort brief
Teva Litigations and Golda Consumer Action
Teva navigates price-fixing defense and inhaler settlements while Golda faces a ₪350 million class action.
Mass Tort
Teva's effort to shield its nationality from jurors reveals how geopolitical conflict creates legal liability risks for Israeli firms operating abroad.
BackgroundTeva faces consolidated multidistrict antitrust lawsuits in Philadelphia alleging generic drug price manipulation. Companies operating in foreign jurisdictions frequently file motions to exclude non-relevant national origin references that could bias jury pools.
- Teva asked the Philadelphia federal judge to bar references to its Israeli corporate headquarters during the upcoming September price-fixing trial.
- Plaintiff insurer Humana agreed not to raise Teva's corporate origin during oral arguments, eliminating one source of jury friction.
- The motion highlights how geopolitical tensions in the Middle East force Israeli multinationals to adjust their legal strategies in foreign courtrooms.
Mass Tort
The certified ₪350M suit against Golda signals strict judicial enforcement of nutrition labeling rules — setting up massive financial exposure for Israeli food chains.
BackgroundIsrael's Consumer Protection Law strictly defines permissible health and nutritional claims on food products. District courts certify class action lawsuits when laboratory evidence suggests systematic consumer deception across retail store chains.
- Laboratory tests revealed sugar-free coffee and hazelnut ice cream contained 6.6g of sugar per 100g compared to the 0.5g statutory limit.
- Judge Iris Rabinovitch-Brun rejected Golda's argument that consumers understood sugar-free to mean no added sugar rather than total sugar content.
- Golda temporarily pulled the affected ice cream lines from store shelves following the court's certification ruling.
Mass Tort
Teva's $35 million settlement dismantles its asthma patent barriers — opening the market to generic rivals and lowering inhaler costs for health funds.
BackgroundGeneric drug makers face growing antitrust scrutiny over patent thickets used to delay competitive generic entries. Health funds sue pharmaceutical manufacturers to recover inflated drug costs caused by suppressed generic competition.
- The $35 million class action settlement resolves claims brought by labor union healthcare funds including Teamsters units.
- Teva agreed to remove 6 disputed patents for its QVAR RediHaler from the FDA Orange Book registry.
- Delisting the patents eliminates antitrust exposure while opening the door for rival manufacturers to launch cheaper generic inhalers.
Unlock the full brief
Sign in to read every signal, takeaway, and source. Free account — Apple, Google, or email.
